InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.044 0.006 (15.79%)+
Announcement
Release
22 Jun 2026 9:17AM
Price at Release
$0.038
Full Release
download
Summary
Emyria Limited, an Australian company specializing in evidence-based mental health treatments, announced the completion of training for its first cohort of therapists in Sydney ahead of the opening of its first NSW-based Empax clinic at Matilda Nepean. The clinic is set to open in Q3 CY2026, marking the company's expansion into New South Wales, which is Australia's largest addressable patient population for mental health services. Emyria's efforts to recruit and train 25 therapists and 6 psychiatrists are part of its strategy to meet the growing demand for innovative mental health therapies, with psychological injuries in NSW having increased by 64% since 2019. The company is on track with its corporate milestones aimed at delivering new therapies across Australia.
Key Points
  • Emyria completed training for 25 therapists and 6 psychiatrists in Sydney.
  • The new Empax clinic is set to open in Q3 CY2026 at Matilda Nepean.
  • Emyria is expanding into New South Wales, Australia's largest mental health market.
  • The company aims to meet the demand for innovative mental health therapies with an increasing trend in psychological injuries.
  • Emyria's national expansion includes over 100 trained clinicians across Western Australia, Victoria, and Queensland.
  • Sydney clinic opening is aligned with corporate milestones for national expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.